Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Operating Income (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Operating Income data on record, last reported at -$36.6 million in Q4 2025.

  • For Q4 2025, Operating Income fell 117.38% year-over-year to -$36.6 million; the TTM value through Dec 2025 reached -$153.3 million, down 141.6%, while the annual FY2025 figure was -$153.3 million, 141.6% down from the prior year.
  • Operating Income reached -$36.6 million in Q4 2025 per AMLX's latest filing, down from -$36.0 million in the prior quarter.
  • Across five years, Operating Income topped out at $210.6 million in Q4 2024 and bottomed at -$122.1 million in Q1 2024.
  • Average Operating Income over 5 years is -$23.1 million, with a median of -$36.3 million recorded in 2025.
  • The widest YoY moves for Operating Income: up 10790.8% in 2024, down 5848.86% in 2024.
  • A 5-year view of Operating Income shows it stood at -$28.3 million in 2021, then crashed by 57.49% to -$44.6 million in 2022, then surged by 104.34% to $1.9 million in 2023, then skyrocketed by 10790.8% to $210.6 million in 2024, then plummeted by 117.38% to -$36.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Income were -$36.6 million in Q4 2025, -$36.0 million in Q3 2025, and -$42.9 million in Q2 2025.